Learning objectives

• Explain the relationship between sub-optimal RAASi therapy and poor cardio-renal outcomes
• Identify patients who would benefit from anti-hyperkalaemia medications
• Select appropriate anti-hyperkalaemia treatments across a range of patient profiles
• Adopt anti-hyperkalaemia medications as an approach to prolong optimal RAASi therapy
• Summarise current guideline recommendations on the use of potassium binding agents